Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine

NCT00217438 is registered in ClinicalTrials.gov with Fred Hutchinson Cancer Center as lead sponsor.

NCT NCT00217438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00217438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Phase III Study of Autologous Transplantation for Patients With Multiple Myeloma Comparing Melphalan 280 mg/m2 + Amifostine With Melphalan 200 mg/m2 + Amifostine
Lead sponsor
Fred Hutchinson Cancer Center
Phase
Phase 3
Overall status
Completed
Start date
July 31, 2005
Completion date
Not reported
Enrollment
130 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

refractory multiple myeloma, stage ii multiple myeloma, stage iii multiple myeloma